https://www.selleckchem.com/pr....oducts/bsj-4-116.htm
3 (39-86) months. Osteolysis of the tibia, talus, and fibula was present preoperatively in 66.7% (12/18), 38.9% (7/18), and 38.9% (7/18) of patients, respectively, with progression of osteolysis in 27.8% (5/18), 11.1% (2/18) and 11.1% (2/18) of patients, respectively. Subsidence of the tibial and talar revision components was observed in 38.9% (7/18) and 55.6% (10/18) of patients, respectively. The median American Orthopaedic Foot Ankle Society (AOFAS) score was 74.5 (26-10 and Foot Function Index (FFI) score 10.2 (0-50.4). Ea

https://www.selleckchem.com/pr....oducts/aprotinin.htm
004). SES-CD was 10 (7-14) and 11 (IQR7-14), and 7 (4-14) and 8 (IQR 4-12;p=0.75)before and after treatment, in the cannabis and placebo groups, respectively. Inflammatory markers (CRP, calprotectin) remained unchanged. Eight weeks of CBD-rich cannabis treatment induced significant clinical and QOL improvement without significant changes in inflammatory parameters or endoscopic scores. The oral CBD-rich cannabis extract was well absorbed. Until further studies are available, cannabis treatment in Crohn's disease should be used only in